Vaccine could cut RSV hospital admissions in babies by 80%, study finds

International research indicates giving infants nirsevimab would cause sharp drop in rates of respiratory syncytial virus infection

A vaccine could reduce by 80% the numbers of babies and young children admitted to hospital with respiratory syncytial virus (RSV), a “groundbreaking” study has found.

The study, published in the peer-reviewed New England Journal of Medicine, involved 8,058 healthy babies aged up to 12 months from the UK, France and Germany, who were approaching their first RSV season.